Science recently learned —50% of medications work through GPCR signaling. But, 99% of existing drugs were discovered by luck: trial, error, observation and testing, over years. The ability to produce stable water-soluble protein replicants is a fundamental new tool that opens many doors: Drug Discovery Our technology provides a critical revitalization of drying pharma pipelines: (i) Addresses compounds with poor solubility (over 40% of drugs) offering increased efficacy and faster, cheaper development. (ii) Enables novel drug candidates for GPCR-mediated diseases: *Examples include: Alzheimer's (GPR3) Parkinson's (GPCR 37) Prostate cancer (GPR68/0GR I) Arteriosclerosis (GPRS 176) Asthma (CCR3.CXCR2) Cancer metastasis (CXCR4) Colon cancer (MASI) Ovarian Cancer (OCR I) Leukemia (P2Y8/P2 R Y8) Diabetes (GPCR 21) Autism (GPCR 63) Bipolar disorder (GPRS 78) Osteoarthritis (GPR22) Lung cancer (GPR87) Breast Cancer (CXCR4) (Plus over 700 others and the list grows almost daily.) Research Tools - Provide our synthetic GPCRQTY materials, duplicating native GPCR functionality in a water-soluble form to research laboratories. Diagnostics - Water-soluble GPCRQTY materials maintain ligand binding ability to specific antigens/receptors, providing a new class of novel, low-cost diagnostics. mAB-Similar Products - New molecular therapeutics: (i) Target-designed to be similar to monoclonal antibodies, but easier to produce; (ii) Engineering mAbQTY to reduce mAb aggregation and increase long-term storage. Autoimmune/Allergy Therapy - Use GPCRQTY as decoy treatment (similar to Enbrel/Etanercept), theoretically for any disease or condition associated with GPCR signaling. Viral Therapeutics - Use Receptors QTY to trap viruses including: HIV, Ebola, Marburg & Lassa - for rapid reduction of viral loads. Molecular Sensors - Use Receptors QTY to create ultra-sensitive bionic detectors. (e.g. a chip-based bionic nose.) Imagine a world in which we could target-design medications to signal through specific GPCR channels. It would change medicin .9 OH2 Laboratories Re-engineering Drug Discovery Company Structure OH2 is an IP development and holding company, structured to form subsidiaries to monetize the benefits our technologies bring to a range of fields: • Drug Discovery • Research Tools • Diagnostics • mAB-Similar Products • Autoimmune/Allergy Therapy • Viral Therapeutics • Molecular Sensors Market Size (Pharma only) GPCR-related pharma is —$425B/year globally. Our technology will grow the market considerably. Our Scientists Shuguang Zhang, Ph.D - Lead Investigator MIT Researcher for 26 years 160 papers, 36 patents issued and pending Last company (3DMatrix) valued at 5800M Prof. Robert Langer MIT Professor for 36 years 1,250+ articles. 220+ major awards 1,030+ patents. 250+ licenses Alexander Rich, M.D. MIT Professor for 56 years 550+ articles. Many awards and honors David Jin, M.D. Practicing Oncologist and Researcher 2012 Top Chief Medical Officer in America 2014 Leading Physicians in the World Our Board David Levy, Ph.D - General Manager and Chairman Marc Rioult, Ph.D - Man. Director, 3DMatrix US & Europe Kevin Munnelly, Ph.D - President and CEO, Gen9 Steve Yang, Ph.D. - Director, Sentilia For more information contact David Levy +1 EFTA01113695